Combination of target therapy and radiation for gastric cancer

• Project/Area Number: 21791215
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Single-year Grants
• Research Field: Radiation science
• Research Institution: Keio University
• Principal Investigator: SHIRAISHI Yu Keio University, 医学部, 助教 (00445339)
• Project Period (FY): 2009 – 2010
• Project Status: Completed (Fiscal Year 2010)
• Budget Amount: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000); Fiscal Year 2010: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000); Fiscal Year 2009: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
• Keywords: 分子標的治療薬 / 放射線治療 / 胃癌

Research Abstract

In this study, we investigated the effect of Trastuzumab, which is a humanized monoclonal antibody that binds to the HER2 protein and mediates growth inhibitory properties on tumors that express HER2, on HER2-positive gastric cancer cells by exposing with X-irradiation. First, we chose 3 different level of HER2 expression on effect of Trastuzumab byreal time PCR. Next, we investigated the effect of Trastuzumab on gastric cancer cells by MTT method. The result showed that the effect of Trastuzumab to HER2-expressing gastric cancer cells was tend to inhibit the growth of the cells. On the other hand, we checked the gastric cancer cells survival rate were decreased with dose-dependent of the X-irradiation. Then, we tested whether the there is any correlation between the Trastuzumab and X-irradiation on HER2-expressing gastric cancer cells. Trastuzumab has been shown to be effective both as single agents and in combination with X-irradiation for the gastric cancer cells with high level of HER2 expression.

Research Products

• [Remarks] ホームページ等 なし